The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients

The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients

Abstract Background In addition to morphological and cytogenetic features, acute myeloid leukemias are characterized by mutations that can be used for target-therapy; also the minimal/measurable residual disease (MRD) could be an important prognostic factor. The purpose of this retrospective study w...

Full description

Bibliographic Details
Main Authors: Serena Salehzadeh, Francesca Guerrini, Umberto Pizzano, Susanna Grassi, Elena Ciabatti, Lorenzo Iovino, Gabriele Buda, Francesco Caracciolo, Edoardo Benedetti, Enrico Orciuolo, Matteo Pelosini, Giovanni Consani, Giovanni Carulli, Maria Rita Metelli, Francesca Martini, Francesco Mazziotta, Elisa Mazzantini, Pietro Rossi, Rita Tavarozzi, Federica Ricci, Mario Petrini, Sara Galimberti
Format: Article
Language:English
Published: BMC 2019-04-01
Series:Cancer Cell International
Subjects:
AML
FLT3
NPM1
WT1
ASXL1
TP53
Online Access:http://link.springer.com/article/10.1186/s12935-019-0807-0

Internet

http://link.springer.com/article/10.1186/s12935-019-0807-0

Similar Items